Munich Cancer Registry - tumorregister-muenchen.de€¦ · 2016, and are represented by colored...

Munich Cancer Registry

�Incidence and Mortality �Selection Matrix �Homepage �Deutsch

ICD-10 C43: Malignant melanoma

Survival

Year of diagnosis 1988-1997 1998-2018

Patients 3,167 19,101

Diseases 3,232 20,050

Cases evaluated 2,932 15,134

Creation date 01/10/2020

Export date 12/31/2019

Population 4.86 m

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC43__E-ICD-10-C43-Malignant-melanoma-survival.pdf

BERLIN

GERMANY

MUNICH

BAVARIA

https://www.tumorregister-muenchen.de/en/facts/base/bC43__E-ICD-10-C43-Malignant-melanoma-incidence-and-mortality.pdf

https://www.tumorregister-muenchen.de/en/facts/specific_analysis.php

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/facts/surv/sC43__G-ICD-10-C43-Malignes-Melanom-Survival.pdf

INDEX ICD-10 C43: Malignant melanoma of 14

MCR sC43__E-ICD-10-C43-Malignant-melanoma-survival.pdf 01/10/2020

Index of figures and tables

Fig./Tbl. Page

1a Relative survival by period of diagnosis (chart) 3

1b Survival by period of diagnosis (table) 3

2a Survival by sex (chart) 4

2b Survival by sex (table) 4

3a Observed survival by age category (chart) 5

3b Relative survival by age category (chart) 5

3c Survival by age category (table) 6

4a Relative survival by tumor thickness (chart) 7

4b Survival by tumor thickness (table) 7

4c Relative survival by tumor thickness (chart) 8

4d Survival by tumor thickness (table) 8

4e Conditional survival by tumor thickness (chart) 9

4f Conditional survival by tumor thickness (table) 9

5a Time to first progression (chart) 10

5b Time to first progression (table) 10

5c Observed post-progression survival (chart) 12

5d Observed post-progression survival (table) 12

5e Observed post-progression survival by period of progression (chart) 13

5f Observed post-progression survival by period of progression (table) 13

GENERAL ICD-10 C43: Malignant melanoma of 14


Figure 1a. Relative survival of patients with malignant melanoma by period of diagnosis. Included in the evaluation are 17,399 cases diagnosed between 1988 and 2017.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2016, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis

1988-1997 1998-2006 2007+ n=2,929 n=5,203 n=9,267

Years obs. % rel. % obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0 100.0 100.0

1 97.2 99.0 96.1 97.8 95.9 97.7

2 92.9 96.3 91.9 95.4 92.1 95.5

3 90.0 94.9 88.1 93.0 89.0 94.0

4 86.9 93.4 85.2 91.4 86.7 93.2

5 84.1 92.0 82.9 90.5 84.4 92.4

6 81.6 90.7 80.7 89.6 82.2 91.5

7 79.4 89.9 78.5 88.6 79.6 90.3

8 77.2 89.0 76.1 87.4 78.1 90.2

9 75.4 88.4 74.3 86.8 75.8 89.2

10 73.5 87.7 72.4 86.1

11 71.5 86.8 70.6 85.4

12 69.4 85.8 69.0 84.9

13 67.5 85.1 67.1 84.1

14 65.7 84.3 65.3 83.3

15 64.3 84.1 63.4 82.4

Table 1b. Observed (obs.) and relative (rel.) survival of patients with malignant melanoma by period of diagnosis for period 1988-2017 (N=17,399).

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinPeriod of diagnosis

% N=17,399Relative survival 1988-2017

Period of diagnosis

1988-1997n=2,929 16.8%

1998-2006n=5,203 29.9%

2007+n=9,267 53.3%

SEER 2000-2016

n=219,860



Figure 2a. Survival of patients with malignant melanoma by sex. Included in the evaluation are 14,470 cases diagnosed between 1998 and 2017.

Sex Male Female n=7,260 n=7,210

Years obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0

1 95.1 97.2 96.8 98.3

2 90.5 94.5 93.5 96.4

3 86.6 92.3 90.7 94.9

4 83.6 90.9 88.6 94.0

5 81.2 90.2 86.4 93.0

6 78.7 89.2 84.5 92.2

7 76.0 88.1 82.4 91.2

8 73.4 86.9 80.8 90.7

9 71.5 86.5 78.8 89.7

10 69.2 85.5 76.9 88.8

11 67.3 85.0 75.1 88.0

12 65.5 84.6 73.8 87.6

13 63.5 83.9 71.8 86.5

14 61.2 82.7 70.5 86.2

15 59.3 81.9 68.7 85.2

Table 2b. Observed (obs.) and relative (rel.) survival of patients with malignant melanoma by sex for period 1998-2017 (N=14,470).

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinSex

% N=14470Survival 1998-2017


% N=14470Survival 1998-2017


% N=14,470Survival 1998-2017

Sex

Malen=7,260 50.2%

Femalen=7,210 49.8%

ObservedExpectedRelative



Figure 3a. Observed survival of patients with malignant melanoma by age category. Included in the evaluation are 17,399 cases diagnosed between 1988 and 2017.

Figure 3b. Relative survival of patients with malignant melanoma by age category. Included in the evaluation are 17,399 cases diagnosed between 1988 and 2017.

0

10

20

30

40

50

60

70

80

90

100

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinAge category

% N=17,399Observed survival 1988-2017

Age category

0-49 yrsn=5,740 33.0%

50-59 yrsn=3,432 19.7%

60-69 yrsn=3,792 21.8%

70+ yrsn=4,435 25.5%

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinAge category


Age category

0-49 yrsn=5,740 33.0%

50-59 yrsn=3,432 19.7%

60-69 yrsn=3,792 21.8%

70+ yrsn=4,435 25.5%



Age category 0-49 yrs 50-59 yrs 60-69 yrs 70+ yrs n=5,740 n=3,432 n=3,792 n=4,435

Years obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

1 98.6 98.7 97.5 98.0 96.8 98.1 91.4 96.7

2 96.7 97.0 94.9 96.0 93.8 96.4 82.7 92.7

3 95.5 95.9 92.5 94.2 90.5 94.6 76.1 90.3

4 94.3 94.9 90.9 93.2 87.6 93.1 70.8 89.3

5 93.4 94.2 89.4 92.4 85.6 92.6 65.3 87.8

6 92.6 93.5 88.2 92.0 83.5 92.1 59.9 86.1

7 91.6 92.7 86.9 91.4 81.4 91.8 54.5 84.2

8 90.8 92.1 85.5 90.7 79.5 91.7 49.9 83.0

9 90.0 91.6 84.4 90.6 77.3 91.4 45.8 82.5

10 89.7 91.5 83.1 90.2 75.0 91.2 40.4 79.5

11 89.1 91.1 82.2 90.3 72.5 90.8 36.2 78.1

12 88.3 90.8 81.2 90.4 70.2 90.9 32.3 76.8

13 87.7 90.4 80.0 90.4 67.4 90.4 28.4 75.1

14 87.2 90.2 78.2 89.8 65.0 90.4 25.0 73.9

15 86.9 90.3 77.0 89.9 62.3 90.6 21.8 72.8

Table 3c. Observed (obs.) and relative (rel.) survival of patients with malignant melanoma by age category for period 1988-2017 (N=17,399).



Figure 4a. Relative survival of patients with malignant melanoma by tumor thickness. For 16,548 of 17,399 cases diagnosed between 1988 and 2017 valid data could be obtained for this item. For a total of 14,764 cases an evaluable classification was established. The grey line represents the subgroup of 2,635 patients with missing values regarding tumor thickness (15.1 % of 17,399 patients, the percent values of all other categories are related to n=14,764).

Tumor thickness <=1.0 mm 1.01 - 2 mm 2.01 - 4 mm >4 mm NS n=9,826 n=2,452 n=1,481 n=1,005 n=2,635

Years obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

1 99.4 100.8 98.6 100.3 96.0 98.6 85.5 89.1 86.0 88.0

2 98.1 101.0 95.8 99.1 87.5 92.4 68.7 74.3 78.2 81.7

3 97.2 101.5 92.4 97.3 78.4 84.9 57.7 64.5 72.6 77.5

4 95.8 101.6 89.1 95.5 72.9 80.9 50.1 57.6 69.4 75.6

5 94.5 101.7 86.1 93.9 68.3 77.6 44.6 52.8 66.3 73.6

6 93.1 101.9 82.7 91.8 64.0 74.6 40.3 48.9 63.3 71.6

7 91.4 101.7 80.2 90.5 60.5 72.4 36.2 45.2 60.2 69.4

8 90.0 101.7 76.7 88.1 57.1 70.0 33.8 43.2 58.0 68.1

9 88.4 101.6 74.5 87.1 53.5 67.2 32.2 42.0 56.0 67.0

10 86.4 100.9 72.2 86.0 50.4 64.8 30.7 41.0 54.4 66.2

11 84.6 100.5 69.9 84.8 48.9 64.3 29.3 40.1 52.1 64.6

12 83.1 100.3 67.3 83.2 47.4 63.9 27.8 39.1 49.8 63.0

13 81.2 99.8 65.4 82.4 45.8 63.2 26.1 37.7 47.4 61.0

14 79.6 99.5 62.7 80.5 43.2 61.0 25.3 37.1 46.0 60.2

15 78.0 99.2 61.7 80.7 41.2 59.2 23.9 36.1 43.9 58.7

Table 4b. Observed (obs.) and relative (rel.) survival of patients with malignant melanoma by tumor thickness for period 1988-2017 (N=14,764).

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinTumor thickness


Tumor thickness

<=1.0 mmn=9,826 66.6%

1.01 - 2 mmn=2,452 16.6%

2.01 - 4 mmn=1,481 10.0%

>4 mmn=1,005 6.8%

NSn=2,635 17.8%



Figure 4c. Relative survival of patients with malignant melanoma by tumor thickness. For 13,768 of 14,470 cases diagnosed between 1998 and 2017 valid data could be obtained for this item. For a total of 12,190 cases an evaluable classification was established. The grey line represents the subgroup of 2,280 patients with missing values regarding tumor thickness (15.8 % of 14,470 patients, the percent values of all other categories are related to n=12,190).

Tumor thickness <=1.0 mm 1.01 - 2 mm 2.01 - 4 mm >4 mm NS n=8,142 n=1,964 n=1,222 n=862 n=2,280

Years obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

1 99.4 100.8 98.7 100.4 95.8 98.5 84.8 88.4 85.5 87.5

2 98.2 101.0 96.1 99.5 87.6 92.7 69.1 74.8 77.6 81.2

3 97.2 101.4 92.6 97.5 78.3 85.0 58.0 64.8 72.2 77.1

4 95.9 101.6 89.4 95.8 72.7 81.0 50.2 57.5 69.3 75.5

5 94.7 101.8 86.8 94.6 67.9 77.5 45.0 53.1 66.3 73.7

6 93.4 102.0 83.9 93.0 63.9 74.7 41.4 50.1 62.9 71.3

7 91.7 101.7 81.8 92.3 60.1 72.0 37.1 46.1 59.6 68.9

8 90.1 101.6 78.7 90.4 57.2 70.3 34.3 43.8 57.4 67.7

9 88.6 101.5 76.4 89.3 53.8 67.9 32.1 41.8 55.1 66.3

10 86.6 100.8 74.0 88.1 50.4 65.1 30.3 40.3 53.6 65.7

11 85.0 100.6 71.2 86.4 49.4 65.2 28.1 38.2 51.2 64.0

12 83.7 100.7 68.9 85.2 47.5 64.2 26.6 37.3 49.4 63.0

13 81.8 100.1 67.3 84.7 46.3 63.9 24.9 35.5 46.2 60.1

14 80.2 99.8 65.2 83.5 44.1 62.5 24.0 34.9 43.9 58.2

15 78.2 99.0 63.8 83.4 41.3 59.5 41.9 56.7

Table 4d. Observed (obs.) and relative (rel.) survival of patients with malignant melanoma by tumor thickness for period 1998-2017 (N=12,190).

0

10

20

30

40

50

60

70

80

90

100

110

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15



Tumor thickness

<=1.0 mmn=8,142 66.8%

1.01 - 2 mmn=1,964 16.1%

2.01 - 4 mmn=1,222 10.0%

>4 mmn=862 7.1%

NSn=2,280 18.7%



Figure 4e. Conditional relative 5-year survival of patients with malignant melanoma by tumor thickness. For 16,548 of 17,399 cases diagnosed between 1988 and 2017 valid data could be obtained for this item. For a total of 14,764 cases an evaluable classification was established. The grey line represents the subgroup of 2,635 patients with missing values regarding tumor thickness (15.1 % of 17,399 patients, the percent values of all other categories are related to n=14,764).

Tumor thickness <=1.0 mm 1.01 - 2 mm 2.01 - 4 mm >4 mm NS

Cond. surv. %

Cond. surv. %

Cond. surv. %

Cond. surv. %

Cond. surv. %

Years n 5 yrs n 5 yrs n 5 yrs n 5 yrs n 5 yrs 0 9,826 101.7 2,452 93.9 1,481 77.6 1,005 52.8 2,635 73.6

1 9,144 101.4 2,307 91.7 1,358 76.1 802 55.3 2,139 81.7

2 8,542 101.2 2,134 91.9 1,179 79.2 602 61.7 1,868 85.5

3 7,907 101.0 1,944 91.4 998 83.6 471 68.3 1,667 88.8

4 7,236 101.1 1,760 92.3 868 84.7 386 74.7 1,488 89.9

5 6,531 100.5 1,568 93.0 758 85.4 312 79.8 1,264 91.5

6 5,821 100.2 1,379 94.0 660 88.4 245 84.2 1,093 92.0

7 5,157 100.5 1,222 93.8 566 90.9 189 89.1 930 92.7

8 4,597 100.1 1,073 95.6 490 93.3 156 90.1 782 91.5

9 4,024 100.1 963 94.6 419 94.1 139 90.8 649 92.0

10 3,580 100.6 846 96.3 351 95.0 115 90.4 558 90.8

Table 4f. Conditional relative 5-year survival of patients with malignant melanoma by tumor thickness for period 1988-2017 (N=14,764).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup tumor thickness=“<=1.0 mm”, who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 101.0% (n=7,907).

0

10

20

30

40

50

60

70

80

90

100

110

Time since diagnosis (years)

0 1 2 3 4 5 6 7 8 9 10


% N=14,764Conditional relative 5 year survival 1988-2017

Tumor thickness

<=1.0 mmn=9,826 66.6%

1.01 - 2 mmn=2,452 16.6%

2.01 - 4 mmn=1,481 10.0%

>4 mmn=1,005 6.8%

NSn=2,635 15.1%

PROGRESSION ICD-10 C43: Malignant melanoma of 14


Figure 5a. Time to first progression of 14,215 patients with malignant melanoma diagnosed between 1998 and 2017 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Type of progression

Any type (CI) Any type (1-KM) Distant

metastasis (CI)

Distant metast. (1-

KM) Locoreg. relapse (CI) Locoreg. rel. (1-KM) NOS (CI)

N 13,587 13,587 13,595 13,595 14,215 14,215 14,207 Events 1,747 1,747 1,342 1,342 838 838 178

compet. 1,368 1,505 2,555 2,936 Years % % % % % % %

0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

1 3.9 3.9 2.3 2.3 2.0 2.0 0.5

2 7.3 7.4 4.8 4.8 3.7 3.9 0.8

3 9.6 9.8 6.8 7.0 4.8 5.0 0.9

4 10.9 11.1 8.2 8.4 5.3 5.6 1.0

5 12.0 12.3 9.1 9.4 5.7 6.0 1.1

6 13.0 13.4 10.0 10.4 6.0 6.5 1.2

7 13.7 14.1 10.6 11.0 6.3 6.8 1.3

8 14.2 14.7 11.0 11.5 6.5 7.0 1.3

9 14.9 15.4 11.5 12.1 6.7 7.3 1.4

10 15.4 16.0 12.0 12.6 6.8 7.4 1.5

11 15.8 16.6 12.4 13.1 7.0 7.7 1.6

12 16.1 16.9 12.8 13.6 7.1 7.8 1.6

13 16.4 17.3 13.1 13.9 7.2 8.0 1.6

14 16.8 17.7 13.2 14.1 7.4 8.2 1.7

15 17.0 18.0 13.3 14.3 7.5 8.4 1.7

0

2

4

6

8

10

12

14

16

18

20

Years

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ICD-10 C43: Malignant melanoma of skinProgressionsform

% N=14,215Time to first progression (TTP) 1998-2017

Type of progression

Any type (CI)Events=1,756

Any type (1-KM)Events=1,756

Distant metastasis (CI)Events=1,347

Distant metast. (1-KM)Events=1,347

Locoreg. relapse (CI)Events=843

Locoreg. rel. (1-KM)Events=843

NOS (CI)Events=181

NOS (1-KM)Events=181



Type of progression

cont'd NOS (1-KM) N 14,207

Events 178 compet. Years %

0 0.0

1 0.5

2 0.8

3 0.9

4 1.0

5 1.2

6 1.3

7 1.4

8 1.5

9 1.6

10 1.7

11 1.7

12 1.7

13 1.8

14 1.9

15 2.0

Table 5b. Time to first progression of patients with malignant melanoma for period 1998-2017 (N=14,215), also showing the total of progression events (Events) and of deaths as competing risk (compet.).



Figure 5c. Observed post-progression survival of 2,143 patients with malignant melanoma diagnosed between 1998 and 2017. These 2,143 patients with documented progression events during their course of disease represent 15.1 % of the totally 14,215 evaluated cases (incl. M1, n=628, 4.4 %). Patients with cancer relapse documented via death certificates only were excluded (n=241, 1.7 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potientially considered in more than one subgroup.

Type of progression

Any type Distant metastasis Locoregional relapse NOS n=2,143 n=1,698 n=842 n=142

Years % % % % 0 100.0 100.0 100.0 100.0

1 61.4 50.3 74.1 80.3

2 45.7 33.9 57.9 67.0

3 37.0 26.1 48.4 52.0

4 32.5 22.4 42.3 49.1

5 29.8 20.6 38.5 43.9

6 27.2 18.7 34.5 41.5

7 25.1 16.6 32.1 38.5

8 23.7 15.6 30.5

9 22.3 14.3 29.3

10 21.4 14.1 27.6

Table 5d. Observed post-progression survival of patients with malignant melanoma for period 1998-2017 (N=2,143).

0

10

20

30

40

50

60

70

80

90

100

Years

0 1 2 3 4 5 6 7 8 9 10

ICD-10 C43: Malignant melanoma of skinProgression type

% N=2,143Observed post-progression survival 1998-2017

Type of progression

Any typen=2,143 100.0%

Distant metastasisn=1,698 79.2%

Locoregional relapsen=842 39.3%

NOSn=142 6.6%



Figure 5e. Observed post-progression (distant metastasis) survival of 2,184 patients with malignant melanoma diagnosed between 1988 and 2017 by period of progression.

Period of progression 1988-1997 1998-2006 2007+ n=286 n=662 n=1,236

Years % % % 0 100.0 100.0 100.0

1 51.0 50.5 51.1

2 37.0 35.2 34.5

3 30.5 27.9 26.5

4 26.0 22.6 23.2

5 23.1 20.9 21.2

6 19.7 19.1 18.8

7 18.2 16.8 16.6

8 16.7 16.0 15.2

9 15.6 14.7

10 15.2 14.5

Table 5f. Observed post-progression (distant metastasis) survival of patients with malignant melanoma for period 1988-2017 by period of progression (N=2,184).

0

10

20

30

40

50

60

70

80

90

100

Years

0 1 2 3 4 5 6 7 8 9 10

ICD-10 C43: Malignant melanoma of skinType of Progression: Distant metastasis

% N=2,184Observed post-progression survival by period of progression date 1988-2017

Period of progression

1988-1997n=286 13.1%

1998-2006n=662 30.3%

2007+n=1,236 56.6%

USAGE ICD-10 C43: Malignant melanoma of 14


Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause

RS Relative survival Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival

AS Assembled survival Assembled chart of observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving a given period of time

TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C43: Malignant melanoma [Internet]. 2020 [updated 2020 Jan 10; cited 2020 Mar 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC43__E-ICD-10-C43-Malignant-melanoma-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Munich Cancer Registry - tumorregister-muenchen.de€¦ · 2016, and are represented by colored...

Documents

Transcript of Munich Cancer Registry - tumorregister-muenchen.de€¦ · 2016, and are represented by colored...